PDF(Pubmed)
Abstract：
UNASSIGNED: Current management of chronic cough is largely based on sequential therapeutic trials. The concept of treatable traits was first introduced for individualized treatment of chronic airway diseases; however, it has emerged as a potentially useful strategy in revising the management of chronic cough. This narrative review aimed to analyze the literature to determine if fractional exhaled nitric oxide (FeNO) is a treatable trait in chronic cough, compared to other type 2 biomarkers, and to summarize current knowledge and gaps in the clinical application.
UNASSIGNED: An online electronic search was performed on PubMed, Web of Science, and Scopus of English-language literature with following keywords: cough, nitric oxide (NO), eosinophils, biomarker, and treatable trait. Relevance and eligibility of each article were assessed by one or more of the authors and a narrative review was composed.
UNASSIGNED: Eosinophilic or type 2 airway inflammation is a major treatable trait in patients with chronic cough. Induced sputum tests are regarded as the gold standard for defining inflammatory phenotype, however, technically demanding and cannot be widely applied in clinical practice. FeNO, a practical biomarker, has emerged as an alternative to induced sputum analyses. Mechanistic and clinical evidence indicated that FeNO had a potential for diagnostic utility and treatment response predictability.
UNASSIGNED: FeNO measurement may help to identify patients with chronic cough that will benefit from corticosteroid treatment. Further studies are warranted to determine the diagnostic roles of FeNO in the management of patients with chronic cough.
UNASSIGNED: An online electronic search was performed on PubMed, Web of Science, and Scopus of English-language literature with following keywords: cough, nitric oxide (NO), eosinophils, biomarker, and treatable trait. Relevance and eligibility of each article were assessed by one or more of the authors and a narrative review was composed.
UNASSIGNED: Eosinophilic or type 2 airway inflammation is a major treatable trait in patients with chronic cough. Induced sputum tests are regarded as the gold standard for defining inflammatory phenotype, however, technically demanding and cannot be widely applied in clinical practice. FeNO, a practical biomarker, has emerged as an alternative to induced sputum analyses. Mechanistic and clinical evidence indicated that FeNO had a potential for diagnostic utility and treatment response predictability.
UNASSIGNED: FeNO measurement may help to identify patients with chronic cough that will benefit from corticosteroid treatment. Further studies are warranted to determine the diagnostic roles of FeNO in the management of patients with chronic cough.
摘要：
■目前慢性咳嗽的管理主要基于序贯治疗试验。可治疗性状的概念首次被引入到慢性气道疾病的个体化治疗中；然而，它已成为修订慢性咳嗽管理的潜在有用策略。这篇叙述性综述旨在分析文献，以确定呼出气一氧化氮（FeNO）是否是慢性咳嗽的可治疗特征，与其他2型生物标志物相比，总结目前临床应用的知识和差距。
■在PubMed上进行了在线电子搜索，WebofScience,和英语文学的Scopus，关键词如下：咳嗽，一氧化氮（NO），嗜酸性粒细胞,生物标志物，和可治疗的特征。由一位或多位作者评估每篇文章的相关性和资格，并撰写叙述性评论。
■嗜酸性粒细胞或2型气道炎症是慢性咳嗽患者的主要可治疗特征。诱导痰试验被认为是定义炎症表型的金标准，然而,技术要求高,不能广泛应用于临床。FeNO,一个实用的生物标志物，已成为诱导痰分析的替代方法。机制和临床证据表明，FeNO具有诊断效用和治疗反应可预测性的潜力。
■FeNO测定可能有助于识别从皮质类固醇治疗中获益的慢性咳嗽患者。需要进一步的研究来确定FeNO在慢性咳嗽患者治疗中的诊断作用。
■在PubMed上进行了在线电子搜索，WebofScience,和英语文学的Scopus，关键词如下：咳嗽，一氧化氮（NO），嗜酸性粒细胞,生物标志物，和可治疗的特征。由一位或多位作者评估每篇文章的相关性和资格，并撰写叙述性评论。
■嗜酸性粒细胞或2型气道炎症是慢性咳嗽患者的主要可治疗特征。诱导痰试验被认为是定义炎症表型的金标准，然而,技术要求高,不能广泛应用于临床。FeNO,一个实用的生物标志物，已成为诱导痰分析的替代方法。机制和临床证据表明，FeNO具有诊断效用和治疗反应可预测性的潜力。
■FeNO测定可能有助于识别从皮质类固醇治疗中获益的慢性咳嗽患者。需要进一步的研究来确定FeNO在慢性咳嗽患者治疗中的诊断作用。
